{"gene":"APOA4","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1986,"finding":"The human APOA4 gene contains only two introns (unlike APOA1 and APOC3 which have three), with introns separating sequences encoding the signal peptide and amphipathic domains, indicating APOA4, APOA1, and APOC3 share a common evolutionary ancestor and APOA4 lost one ancestral intron during evolution.","method":"Gene isolation, restriction mapping, and structural characterization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct gene structural analysis with functional domain mapping","pmids":["3095836"],"is_preprint":false},{"year":2016,"finding":"The lncRNA APOA4-AS directly interacts with the mRNA-stabilizing protein HuR to stabilize APOA4 mRNA; knockdown of APOA4-AS reduces APOA4 expression both in vitro and in vivo, and deletion of HuR dramatically reduces both APOA4-AS and APOA4 transcripts.","method":"RNA pulldown, RIP assay, siRNA knockdown in vitro and in vivo (ob/ob mice), quantitative PCR","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (pulldown, knockdown in vitro and in vivo, rescue) in single study","pmids":["27131369"],"is_preprint":false},{"year":2019,"finding":"ApoA4 functions as a sphingosine 1-phosphate (S1P) chaperone: recombinant ApoA4 directly binds S1P, activates multiple S1P receptors, and promotes vascular endothelial barrier function, identified in ApoM- and albumin-double-knockout mice that retain ~25% plasma S1P.","method":"Recombinant protein binding assay, S1P receptor activation assay, endothelial barrier function assay, ApoM/albumin double-KO mouse model","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted binding, receptor activation, functional assay, and genetic KO model with multiple orthogonal readouts","pmids":["31462513"],"is_preprint":false},{"year":2021,"finding":"LRP1 (low-density lipoprotein receptor-related protein 1) is identified as a receptor for APOA4 in adipose tissue; LRP1 co-localizes and co-immunoprecipitates with APOA4 in adipocytes, their interaction is enhanced during lipid feeding, and LRP1 knockdown abrogates APOA4-induced glucose uptake and PI3K-AKT activation in 3T3-L1 adipocytes.","method":"Co-immunoprecipitation coupled with mass spectrometry, co-localization (immunofluorescence), siRNA knockdown, glucose uptake assay, PI3K-AKT signaling assay","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP/MS, co-localization, KD with defined functional phenotype and signaling readout","pmids":["34168225"],"is_preprint":false},{"year":2017,"finding":"ApoA4 stimulates SERPINA3 (serine proteinase inhibitor) gene expression in mouse hepatocytes by binding nuclear receptors NR4A1 and NR1D1, which then act on the SERPINA3 promoter; confirmed by ChIP, luciferase reporter assay, and siRNA-mediated knockdown of NR4A1 or NR1D1.","method":"ChIP assay, luciferase reporter assay, RNA interference-mediated knockdown, in vivo and in vitro expression assays","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (ChIP, luciferase, RNAi) in single study confirming transcriptional mechanism","pmids":["28412351"],"is_preprint":false},{"year":2011,"finding":"The transcription factor LUMAN (CREB3/LZIP) directly regulates ApoA4 gene expression in dendritic cells; expression of a constitutively active LUMAN in DC cell line D2SC/1 identified ApoA4 as a target gene, confirmed by promoter analysis and silencing studies in bone marrow-derived DCs.","method":"Microarray analysis, constitutively active LUMAN overexpression, bioinformatics-based promoter analysis, gene silencing","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — microarray plus promoter analysis and silencing validation, single lab","pmids":["22209087"],"is_preprint":false},{"year":2015,"finding":"In lipid-free state, ApoA4 exists predominantly as a dimer (up to dimer by crosslinking) with two distinct bands on native gel, while in reconstituted HDL (rHDL) state it forms dimers and trimers; ApoA4 shows lower phospholipid binding ability, lower LCAT activation, and inhibits acetylated LDL uptake only in lipid-free state compared to ApoA-I.","method":"Native gel electrophoresis, BS3 chemical crosslinking, reconstituted HDL formation, LCAT activation assay, acetylated LDL uptake assay","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 1-2 — multiple in vitro biochemical assays in single study characterizing structural and functional properties","pmids":["25997739"],"is_preprint":false},{"year":2021,"finding":"ApoA4 deficiency in mice fed a high-fat diet leads to increased abundance of specific inflammatory macrophage subsets (Cxcl9+ and Cxcl2+ macrophages) and activated granulocytes (Wfdc17+) in liver, with elevated NE and IL-1β expression in these cells, establishing ApoA4 as a suppressor of hepatic immune cell activation in NAFL.","method":"Single-cell RNA sequencing of liver immune cells from WT vs. ApoA4-deficient mice, immunostaining, qRT-PCR","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — scRNA-seq with validation by immunostaining, KO mouse model with defined immune cell phenotype","pmids":["36426356"],"is_preprint":false},{"year":2023,"finding":"Autosomal dominant missense mutations in APOA4 (p.L66V and p.D33N) cause medullary amyloidosis with kidney disease; mutated ApoA4 protein is identified as the predominant amyloid constituent in kidney biopsies by mass spectrometry, and mutations are predicted to expand the amyloidogenic hotspot in the ApoA4 structure.","method":"Whole genome sequencing, kidney biopsy pathology, mass spectrometry of amyloid constituents, clinical genotype-phenotype analysis","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 2 — direct mass spectrometry identification of mutated ApoA4 as amyloid constituent across multiple families and biopsies","pmids":["38096951"],"is_preprint":false},{"year":2021,"finding":"Recombinant human HGF (rh-HGF) induces APOA4 expression in liver via the c-Met receptor; APOA4 induction at mRNA and protein levels was observed in primary cultured human hepatocytes and was inhibited by a c-Met inhibitor, demonstrating c-Met-dependent transcriptional regulation of APOA4.","method":"In vivo mouse liver gene expression analysis, primary human hepatocyte culture, c-Met inhibitor treatment, mRNA and protein quantification","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo experiments with pharmacological inhibitor confirming c-Met dependency","pmids":["33925510"],"is_preprint":false},{"year":2025,"finding":"CD300LG acts as a receptor for triglyceride-rich lipoproteins (TRLs) through a direct interaction with ApoA4 to facilitate TRL clearance at the microvascular endothelium; CD300LG deficiency causes postprandial hypertriglyceridemia in mice.","method":"Direct binding assay (CD300LG–ApoA4 interaction), CD300LG-deficient mouse model, postprandial triglyceride clearance assay, human genetic analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — direct protein interaction demonstrated with KO phenotype, but preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.08.08.669356"],"is_preprint":true},{"year":2025,"finding":"PCSK9 knockdown increases APOA4 expression and APOA4 overexpression reduces PCSK9 expression in AML12 hepatocytes, establishing a reciprocal feedback regulatory relationship between PCSK9 and APOA4 in cholesterol metabolism; TMAO upregulates hepatic PCSK9 and reduces APOA4, promoting lithogenesis.","method":"siRNA knockdown, overexpression plasmids, in vitro hepatocyte model (AML12), in vivo murine cholelithiasis model, RNA sequencing","journal":"Journal of clinical and translational hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function in vitro with in vivo model confirmation","pmids":["40206272"],"is_preprint":false}],"current_model":"APOA4 is a secreted apolipoprotein that functions as a lipid transport protein on HDL and chylomicrons, acts as a chaperone for sphingosine 1-phosphate (binding S1P and activating S1P receptors), signals through the LRP1 receptor in adipose tissue to promote glucose uptake via PI3K-AKT, suppresses hepatic inflammation by inhibiting pro-inflammatory macrophage and granulocyte subsets, interacts with CD300LG at the microvascular endothelium to facilitate triglyceride-rich lipoprotein clearance, regulates SERPINA3 transcription via nuclear receptors NR4A1 and NR1D1, is itself regulated post-transcriptionally by the lncRNA APOA4-AS through HuR-mediated mRNA stabilization and transcriptionally by LUMAN/CREB3 and HGF/c-Met signaling, and amyloidogenic mutations in its N-terminal region can cause autosomal dominant medullary amyloidosis and kidney disease."},"narrative":{"teleology":[{"year":1986,"claim":"Structural analysis of the APOA4 gene established that it shares a common ancestor with APOA1 and APOC3 but lost one ancestral intron, placing it within a linked apolipoprotein gene family and framing subsequent functional studies.","evidence":"Gene isolation, restriction mapping, and intron-exon comparison in human genomic DNA","pmids":["3095836"],"confidence":"High","gaps":["Gene structure alone did not reveal any non-lipid-transport functions","No functional assays performed"]},{"year":2011,"claim":"Identification of LUMAN/CREB3 as a direct transcriptional regulator of APOA4 in dendritic cells revealed that APOA4 expression extends beyond enterocytes and hepatocytes, suggesting immune-relevant roles.","evidence":"Microarray with constitutively active LUMAN overexpression, promoter analysis, and silencing in bone marrow-derived DCs","pmids":["22209087"],"confidence":"Medium","gaps":["Physiological relevance of DC-derived APOA4 not tested in vivo","LUMAN binding site on APOA4 promoter not mapped at nucleotide resolution"]},{"year":2015,"claim":"Biochemical characterization showed that lipid-free APOA4 forms dimers and exhibits distinct functional properties from ApoA-I — including lower LCAT activation and inhibition of acetylated LDL uptake only in lipid-free state — clarifying its mode of action on HDL.","evidence":"Native gel electrophoresis, BS3 crosslinking, reconstituted HDL formation, LCAT activation, and acetylated LDL uptake assays","pmids":["25997739"],"confidence":"Medium","gaps":["No high-resolution structure of ApoA4 dimers or trimers","In vivo relevance of lipid-free vs. lipid-bound conformations not established"]},{"year":2016,"claim":"Discovery that the lncRNA APOA4-AS stabilizes APOA4 mRNA through direct interaction with HuR established a post-transcriptional regulatory axis controlling APOA4 abundance in hepatocytes and in vivo.","evidence":"RNA pulldown, RIP assay, siRNA knockdown in vitro and in ob/ob mice, qPCR","pmids":["27131369"],"confidence":"High","gaps":["Whether APOA4-AS/HuR regulation operates in non-hepatic tissues is unknown","Precise HuR binding site on APOA4 mRNA not mapped"]},{"year":2017,"claim":"ApoA4 was shown to regulate hepatocyte gene expression by inducing SERPINA3 transcription through nuclear receptors NR4A1 and NR1D1, revealing an intracellular signaling role beyond lipid transport.","evidence":"ChIP, luciferase reporter, and siRNA knockdown of NR4A1/NR1D1 in mouse hepatocytes","pmids":["28412351"],"confidence":"High","gaps":["How extracellular ApoA4 activates intracellular nuclear receptors is mechanistically unclear","Downstream physiological consequence of SERPINA3 induction by ApoA4 not defined"]},{"year":2019,"claim":"Identification of ApoA4 as an S1P chaperone that binds S1P and activates S1P receptors to strengthen endothelial barriers expanded its function beyond lipoprotein metabolism to vascular signaling.","evidence":"Recombinant ApoA4 binding assays, S1P receptor activation, endothelial barrier assays, and ApoM/albumin double-KO mice","pmids":["31462513"],"confidence":"High","gaps":["Quantitative contribution of ApoA4-S1P relative to ApoM-S1P and albumin-S1P in vivo not determined","Structural basis of ApoA4-S1P interaction unknown"]},{"year":2021,"claim":"Three concurrent advances defined APOA4's receptor-mediated signaling, anti-inflammatory role, and upstream transcriptional regulation: LRP1 was identified as the adipocyte receptor mediating APOA4-dependent glucose uptake via PI3K-AKT; ApoA4 deficiency was shown to unleash hepatic inflammatory macrophage and granulocyte subsets in NAFL; and HGF/c-Met was established as a transcriptional inducer of APOA4 in hepatocytes.","evidence":"Co-IP/MS and siRNA in 3T3-L1 adipocytes (LRP1); scRNA-seq of WT vs. ApoA4-KO mouse liver (inflammation); rh-HGF treatment of primary human hepatocytes with c-Met inhibitor (HGF/c-Met)","pmids":["34168225","36426356","33925510"],"confidence":"High","gaps":["LRP1-APOA4 interaction domain not mapped","Whether anti-inflammatory effects are direct or secondary to lipid changes is unresolved","In vivo validation of HGF/c-Met–APOA4 axis in human liver not performed"]},{"year":2023,"claim":"Missense mutations (p.L66V, p.D33N) in APOA4 were shown to cause autosomal dominant hereditary medullary amyloidosis, linking the N-terminal region to amyloidogenic propensity and establishing APOA4 as a disease gene.","evidence":"WGS of affected families, kidney biopsy with mass spectrometry identifying mutant ApoA4 as amyloid constituent","pmids":["38096951"],"confidence":"High","gaps":["In vitro amyloid fibril formation assays for these variants not reported","Whether wild-type ApoA4 contributes to sporadic amyloidosis is unknown"]},{"year":2025,"claim":"A reciprocal regulatory relationship between PCSK9 and APOA4 in hepatocytes was demonstrated, linking APOA4 to cholesterol metabolism and cholelithiasis pathways.","evidence":"siRNA knockdown and overexpression in AML12 hepatocytes with in vivo murine cholelithiasis model","pmids":["40206272"],"confidence":"Medium","gaps":["Mechanism of reciprocal regulation (direct vs. indirect) not defined","Relevance to human gallstone disease not established"]},{"year":null,"claim":"Key unresolved questions include the structural basis of ApoA4's multifunctional activity (lipid transport, S1P chaperoning, receptor engagement), the mechanism by which extracellular ApoA4 activates intracellular nuclear receptors, and whether the anti-inflammatory and glucose-sensitizing functions are interdependent or independent pathways.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of full-length ApoA4 in lipid-bound or lipid-free state","Integrated in vivo model testing S1P, LRP1, and anti-inflammatory functions simultaneously is lacking","Relative contribution of intestinal vs. hepatic APOA4 to systemic functions not dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,6]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[2]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,3,6,8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[6,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8]}],"complexes":[],"partners":["LRP1","HUR","NR4A1","NR1D1","PCSK9","CD300LG"],"other_free_text":[]},"mechanistic_narrative":"APOA4 is a secreted apolipoprotein that functions in lipid transport, immune modulation, glucose homeostasis, and vascular barrier maintenance. It circulates on HDL and chylomicrons, forms dimers and trimers, and serves as a chaperone for sphingosine 1-phosphate (S1P), directly binding S1P and activating S1P receptors to promote endothelial barrier function [PMID:31462513, PMID:25997739]. In adipose tissue, APOA4 signals through the LRP1 receptor to stimulate glucose uptake via PI3K-AKT, and in liver it suppresses pro-inflammatory macrophage and granulocyte activation during high-fat feeding, while also inducing SERPINA3 transcription through nuclear receptors NR4A1 and NR1D1 [PMID:34168225, PMID:36426356, PMID:28412351]. Autosomal dominant missense mutations in the N-terminal amyloidogenic region of APOA4 (p.L66V, p.D33N) cause hereditary medullary amyloidosis with kidney disease [PMID:38096951]."},"prefetch_data":{"uniprot":{"accession":"P06727","full_name":"Apolipoprotein A-IV","aliases":["Apolipoprotein A4"],"length_aa":396,"mass_kda":45.4,"function":"May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P06727/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA4","total_profiled":1310},"omim":[{"mim_id":"621106","title":"TUBULOINTERSTITIAL KIDNEY DISEASE, AUTOSOMAL DOMINANT 6; ADTKD6","url":"https://www.omim.org/entry/621106"},{"mim_id":"620112","title":"APOA1 ANTISENSE RNA, NONCODING; APOA1AS","url":"https://www.omim.org/entry/620112"},{"mim_id":"620058","title":"FAMILIAL APOLIPOPROTEIN GENE CLUSTER DELETION SYNDROME","url":"https://www.omim.org/entry/620058"},{"mim_id":"611998","title":"cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 3; CREB3L3","url":"https://www.omim.org/entry/611998"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":2929.9}],"url":"https://www.proteinatlas.org/search/APOA4"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P06727","domains":[{"cath_id":"1.20.120.20","chopping":"180-359","consensus_level":"medium","plddt":87.725,"start":180,"end":359}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P06727","model_url":"https://alphafold.ebi.ac.uk/files/AF-P06727-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P06727-F1-predicted_aligned_error_v6.png","plddt_mean":80.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA4","jax_strain_url":"https://www.jax.org/strain/search?query=APOA4"},"sequence":{"accession":"P06727","fasta_url":"https://rest.uniprot.org/uniprotkb/P06727.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P06727/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P06727"}},"corpus_meta":[{"pmid":"3095836","id":"PMC_3095836","title":"Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4).","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3095836","citation_count":81,"is_preprint":false},{"pmid":"2903847","id":"PMC_2903847","title":"DNA polymorphism haplotypes of the human apolipoprotein APOA1-APOC3-APOA4 gene cluster.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2903847","citation_count":70,"is_preprint":false},{"pmid":"27131369","id":"PMC_27131369","title":"A long non-coding RNA, APOA4-AS, regulates APOA4 expression depending on HuR in mice.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27131369","citation_count":65,"is_preprint":false},{"pmid":"26491253","id":"PMC_26491253","title":"Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.","date":"2015","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26491253","citation_count":45,"is_preprint":false},{"pmid":"12556235","id":"PMC_12556235","title":"The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects.","date":"2003","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12556235","citation_count":42,"is_preprint":false},{"pmid":"31462513","id":"PMC_31462513","title":"Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/31462513","citation_count":39,"is_preprint":false},{"pmid":"34168225","id":"PMC_34168225","title":"Low-density lipoprotein receptor-related protein 1 (LRP1) is a novel receptor for apolipoprotein A4 (APOA4) in adipose tissue.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34168225","citation_count":38,"is_preprint":false},{"pmid":"21407247","id":"PMC_21407247","title":"Effect of walnut-enriched meat on the relationship between VCAM, ICAM, and LTB4 levels and PON-1 activity in ApoA4 360 and PON-1 allele carriers at increased cardiovascular risk.","date":"2011","source":"European journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21407247","citation_count":37,"is_preprint":false},{"pmid":"26824674","id":"PMC_26824674","title":"Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26824674","citation_count":34,"is_preprint":false},{"pmid":"28412351","id":"PMC_28412351","title":"Effect of ApoA4 on SERPINA3 mediated by nuclear receptors NR4A1 and NR1D1 in hepatocytes.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28412351","citation_count":28,"is_preprint":false},{"pmid":"8838914","id":"PMC_8838914","title":"Population distributions of APOE, APOH, and APOA4 polymorphisms and their relationships with quantitative plasma lipid levels among the Evenki herders of Siberia.","date":"1996","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/8838914","citation_count":25,"is_preprint":false},{"pmid":"20164363","id":"PMC_20164363","title":"APOA1 and APOA4 gene polymorphisms influence the effects of dietary fat on LDL particle size and oxidation in healthy young adults.","date":"2010","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/20164363","citation_count":24,"is_preprint":false},{"pmid":"22209087","id":"PMC_22209087","title":"Analysis of genes regulated by the transcription factor LUMAN identifies ApoA4 as a target gene in dendritic cells.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22209087","citation_count":21,"is_preprint":false},{"pmid":"29675916","id":"PMC_29675916","title":"Serum ApoA4 levels predicted the progression of renal impairment in T2DM.","date":"2018","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29675916","citation_count":21,"is_preprint":false},{"pmid":"26397108","id":"PMC_26397108","title":"Effects of Polymorphisms in APOA4-APOA5-ZNF259-BUD13 Gene Cluster on Plasma Levels of Triglycerides and Risk of Coronary Heart Disease in a Chinese Han Population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26397108","citation_count":20,"is_preprint":false},{"pmid":"21712729","id":"PMC_21712729","title":"APOA4 polymorphism as a risk factor for unfavorable lipid serum profile and depression: a cross-sectional study.","date":"2011","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/21712729","citation_count":19,"is_preprint":false},{"pmid":"36426356","id":"PMC_36426356","title":"Single-cell RNA sequencing reveals a novel inhibitory effect of ApoA4 on NAFL mediated by liver-specific subsets of myeloid cells.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36426356","citation_count":14,"is_preprint":false},{"pmid":"38096951","id":"PMC_38096951","title":"Autosomal dominant ApoA4 mutations present as tubulointerstitial kidney disease with medullary amyloidosis.","date":"2023","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/38096951","citation_count":11,"is_preprint":false},{"pmid":"25997739","id":"PMC_25997739","title":"Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity.","date":"2015","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25997739","citation_count":11,"is_preprint":false},{"pmid":"37357772","id":"PMC_37357772","title":"HDL anti-inflammatory function is impaired and associated with high SAA1 and low APOA4 levels in aneurysmal subarachnoid hemorrhage.","date":"2023","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37357772","citation_count":10,"is_preprint":false},{"pmid":"31607136","id":"PMC_31607136","title":"The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/31607136","citation_count":10,"is_preprint":false},{"pmid":"23096082","id":"PMC_23096082","title":"Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23096082","citation_count":8,"is_preprint":false},{"pmid":"31181149","id":"PMC_31181149","title":"Interaction of polymorphisms in APOA4-APOA5-ZPR1-BUD13 gene cluster and sleep duration on 5-year lipid changes in middle aged and older Chinese.","date":"2019","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/31181149","citation_count":8,"is_preprint":false},{"pmid":"40206272","id":"PMC_40206272","title":"PCSK9 and APOA4: The Dynamic Duo in TMAO-induced Cholesterol Metabolism and Cholelithiasis.","date":"2025","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40206272","citation_count":6,"is_preprint":false},{"pmid":"34938775","id":"PMC_34938775","title":"The Variants at APOA1 and APOA4 Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34938775","citation_count":6,"is_preprint":false},{"pmid":"26485402","id":"PMC_26485402","title":"Transcriptome Reveals 1400-Fold Upregulation of APOA4-APOC3 and 1100-Fold Downregulation of GIF in the Patients with Polycythemia-Induced Gastric Injury.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26485402","citation_count":6,"is_preprint":false},{"pmid":"33403595","id":"PMC_33403595","title":"Depression Augments Plasma APOA4 without Changes of Plasma Lipids and Glucose in Female Adolescents Carrying G Allele of APOA4 rs5104.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/33403595","citation_count":5,"is_preprint":false},{"pmid":"1427832","id":"PMC_1427832","title":"Linkage heterogeneity between the C3 and LDLR and the APOA4 and APOA1 loci in baboons.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1427832","citation_count":5,"is_preprint":false},{"pmid":"39566154","id":"PMC_39566154","title":"Miniaturized 3D-printed ratiometric electrochemical immunosensing platform for ultrasensitive detection of depression biomarker Apo-A4.","date":"2024","source":"Talanta","url":"https://pubmed.ncbi.nlm.nih.gov/39566154","citation_count":3,"is_preprint":false},{"pmid":"2894008","id":"PMC_2894008","title":"NcoI dimorphic site located 8kb 3' to the human apolipoprotein AIV (APOA4) gene.","date":"1988","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2894008","citation_count":3,"is_preprint":false},{"pmid":"27622441","id":"PMC_27622441","title":"LEP, LDLR and APOA4 gene polymorphisms and their relationship with the risk of overweight, obesity and chronic diseases in adults of the State of Sucre, Venezuela.","date":"2016","source":"Biomedica : revista del Instituto Nacional de Salud","url":"https://pubmed.ncbi.nlm.nih.gov/27622441","citation_count":3,"is_preprint":false},{"pmid":"33925510","id":"PMC_33925510","title":"Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112).","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33925510","citation_count":3,"is_preprint":false},{"pmid":"39569650","id":"PMC_39569650","title":"Therapeutic potential of simvastatin in ALS: Enhanced axonal integrity and motor neuron survival through Apoa4 and Alb modulation.","date":"2025","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39569650","citation_count":1,"is_preprint":false},{"pmid":"40665476","id":"PMC_40665476","title":"Genome-wide study links cardiometabolic factors to cognition via APOA4-APOA5-ZPR1-BUD13 and other loci in rural Indians.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40665476","citation_count":1,"is_preprint":false},{"pmid":"39916324","id":"PMC_39916324","title":"Establishment and characterization of liver-specific Apoa4-Cre and Cyp2c11-Cre rat models in juvenile and adult stages.","date":"2025","source":"Animal models and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39916324","citation_count":1,"is_preprint":false},{"pmid":"41684813","id":"PMC_41684813","title":"Wharton's jelly mesenchymal stem cell-secretome enhances skin rejuvenation via ApoA4 and SERPINH1.","date":"2026","source":"Regenerative therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41684813","citation_count":0,"is_preprint":false},{"pmid":"41582167","id":"PMC_41582167","title":"Predictive value of serum apolipoprotein panel (ApoA1 / ApoA2 / ApoA4) as a biomarker for individual radiosensitivity.","date":"2026","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/41582167","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.08.669356","title":"CD300LG is a receptor for triglyceride-rich lipoproteins that facilitates postprandial lipid clearance","date":"2025-08-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.08.669356","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.23.619940","title":"A genotype-phenotype transformer to assess and explain polygenic risk","date":"2024-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.23.619940","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.01.24318258","title":"Extreme MetaboHealth scores in three cohort studies associate with plasma protein markers for inflammation and cholesterol transport","date":"2024-12-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.01.24318258","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23340,"output_tokens":3042,"usd":0.057825},"stage2":{"model":"claude-opus-4-6","input_tokens":6393,"output_tokens":2602,"usd":0.145522},"total_usd":0.203347,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"The human APOA4 gene contains only two introns (unlike APOA1 and APOC3 which have three), with introns separating sequences encoding the signal peptide and amphipathic domains, indicating APOA4, APOA1, and APOC3 share a common evolutionary ancestor and APOA4 lost one ancestral intron during evolution.\",\n      \"method\": \"Gene isolation, restriction mapping, and structural characterization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct gene structural analysis with functional domain mapping\",\n      \"pmids\": [\"3095836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The lncRNA APOA4-AS directly interacts with the mRNA-stabilizing protein HuR to stabilize APOA4 mRNA; knockdown of APOA4-AS reduces APOA4 expression both in vitro and in vivo, and deletion of HuR dramatically reduces both APOA4-AS and APOA4 transcripts.\",\n      \"method\": \"RNA pulldown, RIP assay, siRNA knockdown in vitro and in vivo (ob/ob mice), quantitative PCR\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pulldown, knockdown in vitro and in vivo, rescue) in single study\",\n      \"pmids\": [\"27131369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ApoA4 functions as a sphingosine 1-phosphate (S1P) chaperone: recombinant ApoA4 directly binds S1P, activates multiple S1P receptors, and promotes vascular endothelial barrier function, identified in ApoM- and albumin-double-knockout mice that retain ~25% plasma S1P.\",\n      \"method\": \"Recombinant protein binding assay, S1P receptor activation assay, endothelial barrier function assay, ApoM/albumin double-KO mouse model\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted binding, receptor activation, functional assay, and genetic KO model with multiple orthogonal readouts\",\n      \"pmids\": [\"31462513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRP1 (low-density lipoprotein receptor-related protein 1) is identified as a receptor for APOA4 in adipose tissue; LRP1 co-localizes and co-immunoprecipitates with APOA4 in adipocytes, their interaction is enhanced during lipid feeding, and LRP1 knockdown abrogates APOA4-induced glucose uptake and PI3K-AKT activation in 3T3-L1 adipocytes.\",\n      \"method\": \"Co-immunoprecipitation coupled with mass spectrometry, co-localization (immunofluorescence), siRNA knockdown, glucose uptake assay, PI3K-AKT signaling assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP/MS, co-localization, KD with defined functional phenotype and signaling readout\",\n      \"pmids\": [\"34168225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ApoA4 stimulates SERPINA3 (serine proteinase inhibitor) gene expression in mouse hepatocytes by binding nuclear receptors NR4A1 and NR1D1, which then act on the SERPINA3 promoter; confirmed by ChIP, luciferase reporter assay, and siRNA-mediated knockdown of NR4A1 or NR1D1.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, RNA interference-mediated knockdown, in vivo and in vitro expression assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (ChIP, luciferase, RNAi) in single study confirming transcriptional mechanism\",\n      \"pmids\": [\"28412351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The transcription factor LUMAN (CREB3/LZIP) directly regulates ApoA4 gene expression in dendritic cells; expression of a constitutively active LUMAN in DC cell line D2SC/1 identified ApoA4 as a target gene, confirmed by promoter analysis and silencing studies in bone marrow-derived DCs.\",\n      \"method\": \"Microarray analysis, constitutively active LUMAN overexpression, bioinformatics-based promoter analysis, gene silencing\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — microarray plus promoter analysis and silencing validation, single lab\",\n      \"pmids\": [\"22209087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In lipid-free state, ApoA4 exists predominantly as a dimer (up to dimer by crosslinking) with two distinct bands on native gel, while in reconstituted HDL (rHDL) state it forms dimers and trimers; ApoA4 shows lower phospholipid binding ability, lower LCAT activation, and inhibits acetylated LDL uptake only in lipid-free state compared to ApoA-I.\",\n      \"method\": \"Native gel electrophoresis, BS3 chemical crosslinking, reconstituted HDL formation, LCAT activation assay, acetylated LDL uptake assay\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple in vitro biochemical assays in single study characterizing structural and functional properties\",\n      \"pmids\": [\"25997739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoA4 deficiency in mice fed a high-fat diet leads to increased abundance of specific inflammatory macrophage subsets (Cxcl9+ and Cxcl2+ macrophages) and activated granulocytes (Wfdc17+) in liver, with elevated NE and IL-1β expression in these cells, establishing ApoA4 as a suppressor of hepatic immune cell activation in NAFL.\",\n      \"method\": \"Single-cell RNA sequencing of liver immune cells from WT vs. ApoA4-deficient mice, immunostaining, qRT-PCR\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq with validation by immunostaining, KO mouse model with defined immune cell phenotype\",\n      \"pmids\": [\"36426356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Autosomal dominant missense mutations in APOA4 (p.L66V and p.D33N) cause medullary amyloidosis with kidney disease; mutated ApoA4 protein is identified as the predominant amyloid constituent in kidney biopsies by mass spectrometry, and mutations are predicted to expand the amyloidogenic hotspot in the ApoA4 structure.\",\n      \"method\": \"Whole genome sequencing, kidney biopsy pathology, mass spectrometry of amyloid constituents, clinical genotype-phenotype analysis\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct mass spectrometry identification of mutated ApoA4 as amyloid constituent across multiple families and biopsies\",\n      \"pmids\": [\"38096951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Recombinant human HGF (rh-HGF) induces APOA4 expression in liver via the c-Met receptor; APOA4 induction at mRNA and protein levels was observed in primary cultured human hepatocytes and was inhibited by a c-Met inhibitor, demonstrating c-Met-dependent transcriptional regulation of APOA4.\",\n      \"method\": \"In vivo mouse liver gene expression analysis, primary human hepatocyte culture, c-Met inhibitor treatment, mRNA and protein quantification\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo experiments with pharmacological inhibitor confirming c-Met dependency\",\n      \"pmids\": [\"33925510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CD300LG acts as a receptor for triglyceride-rich lipoproteins (TRLs) through a direct interaction with ApoA4 to facilitate TRL clearance at the microvascular endothelium; CD300LG deficiency causes postprandial hypertriglyceridemia in mice.\",\n      \"method\": \"Direct binding assay (CD300LG–ApoA4 interaction), CD300LG-deficient mouse model, postprandial triglyceride clearance assay, human genetic analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction demonstrated with KO phenotype, but preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.08.08.669356\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PCSK9 knockdown increases APOA4 expression and APOA4 overexpression reduces PCSK9 expression in AML12 hepatocytes, establishing a reciprocal feedback regulatory relationship between PCSK9 and APOA4 in cholesterol metabolism; TMAO upregulates hepatic PCSK9 and reduces APOA4, promoting lithogenesis.\",\n      \"method\": \"siRNA knockdown, overexpression plasmids, in vitro hepatocyte model (AML12), in vivo murine cholelithiasis model, RNA sequencing\",\n      \"journal\": \"Journal of clinical and translational hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function in vitro with in vivo model confirmation\",\n      \"pmids\": [\"40206272\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA4 is a secreted apolipoprotein that functions as a lipid transport protein on HDL and chylomicrons, acts as a chaperone for sphingosine 1-phosphate (binding S1P and activating S1P receptors), signals through the LRP1 receptor in adipose tissue to promote glucose uptake via PI3K-AKT, suppresses hepatic inflammation by inhibiting pro-inflammatory macrophage and granulocyte subsets, interacts with CD300LG at the microvascular endothelium to facilitate triglyceride-rich lipoprotein clearance, regulates SERPINA3 transcription via nuclear receptors NR4A1 and NR1D1, is itself regulated post-transcriptionally by the lncRNA APOA4-AS through HuR-mediated mRNA stabilization and transcriptionally by LUMAN/CREB3 and HGF/c-Met signaling, and amyloidogenic mutations in its N-terminal region can cause autosomal dominant medullary amyloidosis and kidney disease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"APOA4 is a secreted apolipoprotein that functions in lipid transport, immune modulation, glucose homeostasis, and vascular barrier maintenance. It circulates on HDL and chylomicrons, forms dimers and trimers, and serves as a chaperone for sphingosine 1-phosphate (S1P), directly binding S1P and activating S1P receptors to promote endothelial barrier function [PMID:31462513, PMID:25997739]. In adipose tissue, APOA4 signals through the LRP1 receptor to stimulate glucose uptake via PI3K-AKT, and in liver it suppresses pro-inflammatory macrophage and granulocyte activation during high-fat feeding, while also inducing SERPINA3 transcription through nuclear receptors NR4A1 and NR1D1 [PMID:34168225, PMID:36426356, PMID:28412351]. Autosomal dominant missense mutations in the N-terminal amyloidogenic region of APOA4 (p.L66V, p.D33N) cause hereditary medullary amyloidosis with kidney disease [PMID:38096951].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Structural analysis of the APOA4 gene established that it shares a common ancestor with APOA1 and APOC3 but lost one ancestral intron, placing it within a linked apolipoprotein gene family and framing subsequent functional studies.\",\n      \"evidence\": \"Gene isolation, restriction mapping, and intron-exon comparison in human genomic DNA\",\n      \"pmids\": [\"3095836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene structure alone did not reveal any non-lipid-transport functions\", \"No functional assays performed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of LUMAN/CREB3 as a direct transcriptional regulator of APOA4 in dendritic cells revealed that APOA4 expression extends beyond enterocytes and hepatocytes, suggesting immune-relevant roles.\",\n      \"evidence\": \"Microarray with constitutively active LUMAN overexpression, promoter analysis, and silencing in bone marrow-derived DCs\",\n      \"pmids\": [\"22209087\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of DC-derived APOA4 not tested in vivo\", \"LUMAN binding site on APOA4 promoter not mapped at nucleotide resolution\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Biochemical characterization showed that lipid-free APOA4 forms dimers and exhibits distinct functional properties from ApoA-I — including lower LCAT activation and inhibition of acetylated LDL uptake only in lipid-free state — clarifying its mode of action on HDL.\",\n      \"evidence\": \"Native gel electrophoresis, BS3 crosslinking, reconstituted HDL formation, LCAT activation, and acetylated LDL uptake assays\",\n      \"pmids\": [\"25997739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of ApoA4 dimers or trimers\", \"In vivo relevance of lipid-free vs. lipid-bound conformations not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery that the lncRNA APOA4-AS stabilizes APOA4 mRNA through direct interaction with HuR established a post-transcriptional regulatory axis controlling APOA4 abundance in hepatocytes and in vivo.\",\n      \"evidence\": \"RNA pulldown, RIP assay, siRNA knockdown in vitro and in ob/ob mice, qPCR\",\n      \"pmids\": [\"27131369\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether APOA4-AS/HuR regulation operates in non-hepatic tissues is unknown\", \"Precise HuR binding site on APOA4 mRNA not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ApoA4 was shown to regulate hepatocyte gene expression by inducing SERPINA3 transcription through nuclear receptors NR4A1 and NR1D1, revealing an intracellular signaling role beyond lipid transport.\",\n      \"evidence\": \"ChIP, luciferase reporter, and siRNA knockdown of NR4A1/NR1D1 in mouse hepatocytes\",\n      \"pmids\": [\"28412351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How extracellular ApoA4 activates intracellular nuclear receptors is mechanistically unclear\", \"Downstream physiological consequence of SERPINA3 induction by ApoA4 not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of ApoA4 as an S1P chaperone that binds S1P and activates S1P receptors to strengthen endothelial barriers expanded its function beyond lipoprotein metabolism to vascular signaling.\",\n      \"evidence\": \"Recombinant ApoA4 binding assays, S1P receptor activation, endothelial barrier assays, and ApoM/albumin double-KO mice\",\n      \"pmids\": [\"31462513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of ApoA4-S1P relative to ApoM-S1P and albumin-S1P in vivo not determined\", \"Structural basis of ApoA4-S1P interaction unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Three concurrent advances defined APOA4's receptor-mediated signaling, anti-inflammatory role, and upstream transcriptional regulation: LRP1 was identified as the adipocyte receptor mediating APOA4-dependent glucose uptake via PI3K-AKT; ApoA4 deficiency was shown to unleash hepatic inflammatory macrophage and granulocyte subsets in NAFL; and HGF/c-Met was established as a transcriptional inducer of APOA4 in hepatocytes.\",\n      \"evidence\": \"Co-IP/MS and siRNA in 3T3-L1 adipocytes (LRP1); scRNA-seq of WT vs. ApoA4-KO mouse liver (inflammation); rh-HGF treatment of primary human hepatocytes with c-Met inhibitor (HGF/c-Met)\",\n      \"pmids\": [\"34168225\", \"36426356\", \"33925510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"LRP1-APOA4 interaction domain not mapped\", \"Whether anti-inflammatory effects are direct or secondary to lipid changes is unresolved\", \"In vivo validation of HGF/c-Met–APOA4 axis in human liver not performed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Missense mutations (p.L66V, p.D33N) in APOA4 were shown to cause autosomal dominant hereditary medullary amyloidosis, linking the N-terminal region to amyloidogenic propensity and establishing APOA4 as a disease gene.\",\n      \"evidence\": \"WGS of affected families, kidney biopsy with mass spectrometry identifying mutant ApoA4 as amyloid constituent\",\n      \"pmids\": [\"38096951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro amyloid fibril formation assays for these variants not reported\", \"Whether wild-type ApoA4 contributes to sporadic amyloidosis is unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A reciprocal regulatory relationship between PCSK9 and APOA4 in hepatocytes was demonstrated, linking APOA4 to cholesterol metabolism and cholelithiasis pathways.\",\n      \"evidence\": \"siRNA knockdown and overexpression in AML12 hepatocytes with in vivo murine cholelithiasis model\",\n      \"pmids\": [\"40206272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of reciprocal regulation (direct vs. indirect) not defined\", \"Relevance to human gallstone disease not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of ApoA4's multifunctional activity (lipid transport, S1P chaperoning, receptor engagement), the mechanism by which extracellular ApoA4 activates intracellular nuclear receptors, and whether the anti-inflammatory and glucose-sensitizing functions are interdependent or independent pathways.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of full-length ApoA4 in lipid-bound or lipid-free state\", \"Integrated in vivo model testing S1P, LRP1, and anti-inflammatory functions simultaneously is lacking\", \"Relative contribution of intestinal vs. hepatic APOA4 to systemic functions not dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 3, 6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [6, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LRP1\", \"HuR\", \"NR4A1\", \"NR1D1\", \"PCSK9\", \"CD300LG\"],\n    \"other_free_text\": []\n  }\n}\n```"}